# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

> **NCT07117474** · PHASE1 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Subjects With Mild Hypertension

## Interventions

- **DRUG:** HRS-9563, placebo

## Key facts

- **NCT ID:** NCT07117474
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117474, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07117474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*